Stock Events

Precipio 

$6.53
38
+$0.13+2.03% Wednesday 20:00

Statistics

Day High
6.62
Day Low
6.35
52W High
8.99
52W Low
4.31
Volume
11,243
Avg. Volume
10,015
Mkt Cap
9.72M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

11
NOV
Earnings
 

Earnings

11NovExpected
Q4 2022
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.4
-0.64
0.12
0.88
Expected EPS
0.4
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRPO. It's not an investment recommendation.
Alphabet
78395
GOOGL
Apple
68177
AAPL
Microsoft
63621
MSFT
Amazon
59331
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap3.15B
Guardant Health offers liquid biopsy tests similar to Precipio's diagnostic solutions, competing in the cancer diagnostics market.
Exact Sciences
EXAS
Mkt Cap11.4B
Exact Sciences provides cancer screening and diagnostic tests, directly competing with Precipio's diagnostic services.
Fulgent Genetics
FLGT
Mkt Cap683.49M
Fulgent Genetics provides comprehensive genetic testing, competing with Precipio in the genomic diagnostics space.
Thermo Fisher Scientific
TMO
Mkt Cap234.95B
Thermo Fisher Scientific offers a wide range of diagnostics and research products, indirectly competing with Precipio's diagnostic services.
Illumina
ILMN
Mkt Cap20.93B
Illumina provides genomic sequencing services and solutions, competing in the genomics space against Precipio.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen offers sample and assay technologies for molecular diagnostics, competing with Precipio in the diagnostics market.

About

Health Technology
Biotechnology
Manufacturing
Analytical Laboratory Instrument Manufacturing
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Show more...
CEO
Paul Kinnon
Employees
51
Country
US
ISIN
US74019L5030

Listings

XNAS
US
PRPO